ArkVax is revolutionising animal vaccinology
ArkVax aims to bring one of the safest and best proven vaccine families to animals
Combatting Antimicrobial Resistance via a Novel Vaccine Technology
The UN and WHO have recognised that antibiotic overuse in livestock and resulting antimicrobial resistance is a threat to both human and animal health. ArkVax aims to revolutionise animal vaccinology by developing glycan based solutions with the potential to disrupt the antibacterial vaccine space.
£12B
>60Bn
240k
Leading Innovative Vaccine Development Through Advanced Bacterial Engineering
ArkVax specializes in developing glycoconjugate vaccines. These have the potential to transform animal health by offering greater potency and broader protection than current vaccines. ArkVax’s vaccines also have the potential to combat antimicrobial resistance in animal but also humans by conferring protection from zoonotic diseases. Leveraging £30M in grants, extensive glycobiology know-how and strong IP, ArkVax is well positioned to revolutionize the animal health market.
Our technology in simple terms
Our expertise is in the genetic engineering of bacterial cells. We modify them to carry a pay load of a vaccine based on one of the most successful vaccine families used in human medicine.